Juven is a medical food that is manufactured by Abbott Laboratories and used to provide nutritional support under the care of a physician in individuals with muscle wasting due to AIDS or cancer, to promote wound healing following surgery or injury, or when otherwise recommended by a medical professional.[1][2][3] It is a powdered nutritional supplement that contains 3 grams of calcium β-hydroxy β-methylbutyrate, 14 grams of -arginine, and 14 grams of -glutamine per two daily servings.[1]
Juven has been shown to increase lean body mass during clinical trials in individuals with AIDS and cancer, but not rheumatoid cachexia.[4] Clinical trials with Juven for AIDS have also demonstrated improvements in immune status, as measured by a reduced HIV viral load relative to controls and higher CD3+ and CD8+ cell counts.[4] The efficacy of Juven for the treatment of cancer cachexia was also examined in a phase 3 clinical trial which found a strong trend (i.e., p = .08) for an improvement in lean body mass relative to controls; however, according to the authors of the trial itself and a systematic review that included it, the trial did not adequately test the ability of Juven to prevent or reverse the loss of lean body mass in individuals with cancer cachexia since the majority of participants did not complete the study.[6][7] Further research involving the treatment of cancer cachexia with Juven over a period of several months is required to adequately determine treatment efficacy.[6][8]
External links
References
- Product Information: Juven Abbott Nutrition, 7 May 2016, retrieved 6 October 2022^
- Proteins in Human Health and Performance Iowa State University, 13 May 2013, retrieved 31 July 2016^
- Rethinking the formula Nat. Med., May 2013^
- Elderly persons with ICU-acquired weakness: the potential role for β-hydroxy-β-methylbutyrate (HMB) supplementation? Journal of Parenteral and Enteral Nutrition, July 2014^
- The Ratio of Regulatory (FOXP3+) to Total (CD3+) T Cells Determined by Epigenetic Cell Counting and Cardiovascular Disease Risk: A Prospective Case-cohort Study in Non-diabetics eBioMedicine, September 2016^
- Beta-hydroxy-beta-methylbutyrate supplementation in health and disease: a systematic review of randomized trials Amino Acids, December 2013^
- A randomized, double-blind, placebo-controlled trial of a beta-hydroxyl beta-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122) Supportive Care in Cancer, October 2008^
- A systematic review on the role of vitamins, minerals, proteins, and other supplements for the treatment of cachexia in cancer: a European Palliative Care Research Centre cachexia project Journal of Cachexia, Sarcopenia and Muscle, July 2016^